A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, extending a slow debut complicated by coverage questions and doctor concerns. The news came Wednesday as Biogen also confirmed making layoffs among its patient support staff in Raleigh.